DNDI-6174
objective
Progress the pre-clinical development of DNDI-6174 for the treatment of visceral leishmaniasis
project start
2019
current phase of drug development
Drug Discovery
Translational research
Clinical trials
Registration & access
updated 29 Apr 2020
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
Emerging from the leishmaniasis L205 lead optimization series after showing great efficacy in vivo in both mouse and hamster models for visceral leishmaniasis, DNDI-6174 was nominated as a pre-clinical candidate for visceral leishmaniasis in 2019.
Project updates
2019
Planning is underway to start pre-clinical activities in 2020.
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
